1. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020) Authors: Cavo, Michele; Gay, Francesca; Beksac, Meral; Pantani, Lucia; Petrucci, Maria Teresa; Dimopoulos, Meletios A; Dozza, Luca; van der Holt, Bronno; Zweegman, Sonja; Oliva, Stefania; van der Velden, Vincent H J; Zamagni, Elena; Palumbo, Giuseppe A; Patriarca, Francesca; Montefusco, Vittorio; Galli, M... Journal: Lancet Issue: Volume 7:Issue 6(2020) Page Start: e456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Issue 1 (January 2023) Authors: Mina, Roberto; Musto, Pellegrino; Rota-Scalabrini, Delia; Paris, Laura; Gamberi, Barbara; Palmas, Angelo; Aquino, Sara; de Fabritiis, Paolo; Giuliani, Nicola; De Rosa, Luca; Gozzetti, Alessandro; Cellini, Claudia; Bertamini, Luca; Capra, Andrea; Oddolo, Daniela; Vincelli, Iolanda Donatella; Ronco... Journal: Lancet oncology Issue: Volume 24:Issue 1(2023) Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Issue 12 (December 2021) Authors: Gay, Francesca; Musto, Pellegrino; Rota-Scalabrini, Delia; Bertamini, Luca; Belotti, Angelo; Galli, Monica; Offidani, Massimo; Zamagni, Elena; Ledda, Antonio; Grasso, Mariella; Ballanti, Stelvio; Spadano, Antonio; Cea, Michele; Patriarca, Francesca; D'Agostino, Mattia; Capra, Andrea; Giuliani, Ni... Journal: Lancet oncology Issue: Volume 22:Issue 12(2021) Page Start: 1705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases. Issue 3 (13th January 2021) Authors: Castellino, Alessia; Elba, Simona; Sorasio, Roberto; Castellino, Claudia; Bonferroni, Margherita; Grasso, Mariella; Grosso, Enrico; Giacchello, Rosalba; Signorile, Anna Franca; Celeghini, Ivana; Mattei, Daniele; Mordini, Nicola; Foglietta, Myriam; Masturzo, Bianca; Priotto, Roberto; Zonta, Andrea... Journal: Clinical case reports Issue: Volume 9:Issue 3(2021) Page Start: 1066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗